Lin BioScience's receivables is $23M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Lin BioScience (6696.TWO) currently reports a receivables of $23M as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Lin BioScience's receivables history and peer comparisons.
Lin BioScience's receivables changed from $0 to $23M (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Lin BioScience reported $23M in receivables as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current receivables of $23M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Lin BioScience, and consider following 6696.TWO for alerts when major investors trade the stock.
Lin BioScience is classified in the Healthcare sector. On receivables, it currently shows $23M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 6696.TWO with unrelated industries.